Introduction
Upper gastrointestinal involvement in Crohn’s disease (UGI-CD) is heterogeneously defined limiting risk stratification and interpretation of its prognostic significance. UGI disease has been linked to more aggressive clinical outcomes in some cohorts, but variability across definitions and disease subtypes complicates interpretation. Clarifying predictors of disease course in UGI-CD is therefore essential.
Aims & Methods
The aim of this study was to systematically map and contextualize factors associated with disease course and clinical outcomes in upper gastrointestinal Crohn’s disease (UGI-CD). We conducted a PRISMA-ScR–guided scoping review of MEDLINE, Embase, and CENTRAL (inception to November 2025) including studies of adults with UGI-CD reporting prognostic associations. Findings were organized across three domains: factors associated with UGI involvement at diagnosis, comparative outcomes versus non-UGI disease, and predictors of adverse outcomes within UGI-CD. Data were charted using a standardized form and synthesized descriptively using inductive content analysis. Definitions of UGI involvement were extracted where available to contextualize heterogeneity across studies.
Results
Forty-four studies were included, yielding 103 prognostic factor–outcome associations which were grouped into three domains: (1) factors associated with UGI involvement at diagnosis, (2) comparative outcomes versus non-UGI disease, and (3) predictors of adverse outcomes within UGI-CD. Younger age at diagnosis was the most consistently reported factor associated with UGI involvement. Compared with non-UGI disease, UGI involvement was consistently associated with a higher risk of surgery, stricturing complications, and overall disease progression, with variation by anatomic subtype. Within UGI-CD, proximal small bowel involvement, particularly jejunal disease, emerged as the strongest predictor of adverse outcomes compared to esophagogastroduodenal-limited disease. Markers of disease severity, including stricturing or penetrating behaviour and higher endoscopic activity, were associated with increased risk of surgical intervention and recurrence.
Conclusion
UGI-CD represents a high-risk phenotype associated with a more aggressive clinical course. These findings support the need for early risk stratification, particularly in patients with proximal small bowel involvement. Several prognostic factors have been identified, particularly related to age at onset and endoscopic severity. However, the evidence remains heterogeneous. Key gaps include inconsistent disease definitions, lack of validated prognostic biomarkers, and limited data on the impact of modern biologic therapies.
References
1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389:1741-55. doi:10.1016/S0140-6736(16)31711-1.
2. Chin YH, Ng CH, Lin SY, Jain SR, Kong G, Koh JWH, et al. Systematic review with meta-analysis: the prevalence, risk factors and outcomes of upper gastrointestinal tract Crohn’s disease. Dig Liver Dis. 2021;53:1548-1558. doi:10.1016/j.dld.2021.07.037.
3. Tamizifar B, Adibi P, Hadipour M, Mohamadi V. A systematic review and meta-analysis of prevalence and clinical features of upper gastrointestinal tract Crohn’s disease in adults compared to non-UGI types. JGH Open. 2023;7:325-336. doi:10.1002/jgh3.12888.
4. Mao R, Tang R-H, Qiu Y, Chen B-L, Guo J, Zhang S-H, et al. Different clinical outcomes in Crohn’s disease patients with esophagogastroduodenal, jejunal, and proximal ileal disease involvement: is L4 truly a single phenotype? Ther Adv Gastroenterol. 2018;11:1-9. doi:10.1177/1756284818777938.
5. Yuan Y, Sedano R, Solitano V, Nardone OM, Crowley E, Jairath V. Heterogeneity of definition of upper gastrointestinal tract in different guidelines of Crohn’s disease: A scoping review. United European Gastroenterol J. 2024 Dec;12(10):1481-1488. doi:10.1002/ueg2.12697. Epub 2024 Nov 14
Disclosure
RS: has received consulting fees from Abbvie, Alimentiv, Pendopharm and Takeda, speaker’s fees from Abbvie.
CM: has received consulting fees from AbbVie, Alimentiv, Amgen, Anaptys Bio, AVIR Pharma Inc, Bristol Myers Squibb, Celltrion, Domain Therapeutics, Eupraxia, Eli Lilly, Ferring, Forte Biosciences, Fresenius Kabi, Gilead, Janssen, McKesson, Mirador Therapeutics, Pendopharm, Pfizer, Prometheus Biosciences Inc., Roche, Sanofi, Takeda, Tillotts Pharma; speaker's fees from AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Bristol Myers Squibb, Eli Lilly, Ferring, Fresenius Kabi, Janssen, Merck, Organon, Pendopharm, Pfizer, Sanofi, Takeda, Tillotts Pharma; royalties from Springer Publishing; research support from AbbVie, Eli Lilly, Ferring, Pfizer.
SD: has received consultancy fees from AbbVie, Alimentiv Inc., Allergan, Amgen, Applied Molecular Transport, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol.
Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, Morphic, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, Teladoc Health, TiGenix, UCB Inc., Vial, and Vifor; and reports lecture fees from AbbVie, Amgen, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer, and Takeda.
LPB: has received consulting fees from Abbvie , Abivax, Adacyte, Alimentiv, Alfasigma, Amgen, Apini, Applied Molecular Transport, Arena, Banook, BMS, Celltrion, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, GSK, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Iterative Health, Janssen, Lilly, LifeMine, Medac, Mopac, Morphic, MSD, Nordic Pharma, Novartis, Oncodesign, Precision Medicine, ONO Pharma, OSE Immunotherapeuthics , Par' Immune , Pfizer , Prometheus , Roche , Roivant , Samsung , Sandoz , Sanofi, Sorriso, Spyre, Takeda, Teva, ThirtyfiveBio, Tillots, Vectivbio, Vedanta, Ventyx; lecture fees from Abbvie, Alfasigma, Amgen, Arena, Biogen, Celltrion, Ferring, Galapagos, Genentech, Gilead, Iterative Health, Janssen, Lilly, Medac, MSD, Nordic Pharma, Pfizer, Sandoz, Takeda, Tillots.
SS: Research grants from Pfizer.
VJ: has received consulting/advisory board fees from AbbVie, Alimentiv, Anaptyis Bio, Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Avoro Capital, Bristol Myers Squibb, Celltrion, Eli Lilly, Endpoint Health, Enthera, Ensho, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, Gilde Healthcare, GlaxoSmithKline, Genentech, Gilead, Innomar, JAMP, Janssen, Merck, Metacrine, Mylan, MRM Health, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus Biosciences, Reistone Biopharma, Roche, Roivant, Sandoz, Second Genome, Sorriso, Synedgen, Takeda, TD Securities, Teva, Topivert, Ventyx, Vividion; speaker’s fees from, Abbvie, Ferring, Bristol Myers Squibb, Galapagos, Janssen Pfizer Shire, Takeda, Tillotts, Fresenius Kabi.
RE, NN, MS, DL, YY, RM declare no conflicts of interest.